Novoic
Novoic is a clinical stage biotechnology company developing algorithms to detect neurological diseases, such Alzheimer’s disease, in their preclinical stages, by analysing audio-linguistic patterns of speech.
Early detection of Alzheimer disease is needed for effective treatment. Today, less than 1% of patients who develop Alzheimer’s disease have access to early detection. Speech-based testing can offer scalable access for anyone, anywhere.
Novoic uses AI-enabled software to detect subtle cognitive impairment and Alzheimer’s neuropathology, based on how people speak. Novoic’s models accurately detect mild cognitive impairment, including sub-threshold impairment in preclinical Alzheimer’s disease.
Founders
Emil Fristed
CEO
Emil graduated with distinction from the University of Oxford with a Master’s in Neuroscience. He worked in a world-leading auditory neuroscience group (King Group), applying machine learning models to understand the senses; he studied language and how it changes as the brain gets ill. Prior to that he completed a Bachelor’s degree in Molecular Medicine, graduating at the top of his class, and was selected to undertake an independent research project in Alzheimer’s disease during his studies.
Jack Weston
CTO
Jack obtained a PhD in Particle Physics from the University of Cambridge, and a Master of Physics from the University of Oxford. He spent time as a professor at the University of Oxford and is also a research fellow at the Cambridge Institute for Theoretical Cosmology.
Milestones
Founded at Entrepreneur First
Seed (£2.4 million)